^
CD276 underexpression + EGFR mutation
LUAD
EGFR inhibitor
Sensitive: C3 – Early Trials
World J Surg Oncol - 2 days - (New C3)
LMO7-ALK rearrangement
LUAD
crizotinib
Sensitive: C4 – Case Studies
Front Oncol - 3 days - (New C4)
ER mutation
HER2 Negative Breast Cancer
RAD1901
Sensitive: B - Late Trials
J Clin Oncol - 4 days - (New B)
EGFR mutation + RET fusion
NSCLC
osimertinib + pralsetinib
Sensitive: C3 – Early Trials
JTO Clin Res Rep - 4 days - (New C3)
EGFR V786M
LUAD
EGFR inhibitor
Sensitive: C4 – Case Studies
Front Oncol - 4 days - (New C4)
EML4-ALK fusion
NSCLC
alectinib
Sensitive: C3 – Early Trials
Int J Cancer - 5 days - (New C3)
EML4-ALK fusion + TP53 mutation
NSCLC
alectinib
Resistant: C3 – Early Trials
Int J Cancer - 5 days - (New C3)
KRAS G12D
CRC
KS-58
Sensitive: D – Preclinical
Sci Rep - 5 days - (New D)
No biomarker
Astrocytoma
carmustine
Sensitive: A1 - Approval
FDA - 6 days - (New A1)
No biomarker
Ependymoma
carmustine
Sensitive: A1 - Approval
FDA - 6 days - (New A1)
No biomarker
Medulloblastoma
carmustine
Sensitive: A1 - Approval
FDA - 6 days - (New A1)
No biomarker
Glioma
carmustine
Sensitive: A1 - Approval
FDA - 6 days - (New A1)
No biomarker
GBM
carmustine
Sensitive: A1 - Approval
FDA - 6 days - (New A1)
PD-L1 overexpression
NSCLC
atezolizumab + RG6058
Sensitive: B - Late Trials
Roche Press Release - 1 week - (New B)
ROS1 positive
NSCLC
TPX-0005
Sensitive: B - Late Trials
Turning Point Therapeutics Press Release - 1 week - (New B)
ETV6-NTRK3 fusion
Salivary Gland Cancer
larotrectinib
Sensitive: C3 – Early Trials
The Oncologist - 1 week - (New C3)
MSI-H/dMMR
CRC
PD1 inhibitor
Sensitive: C3 – Early Trials
Clin Cancer Res - 1 week - (New C3)
ALK positive
NSCLC
ALK1 inhibitor
Sensitive: C3 – Early Trials
Thorac Cancer - 1 week - (New C3)
CXCR3 overexpression
Urothelial Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Cancer Cell Int - 1 week - (New C3)
CD8 overexpression
Bladder Cancer
atezolizumab
Sensitive: C3 – Early Trials
Eur Urol - 1 week - (New C3)
MGMT deletion
CRC
nivolumab + ipilimumab + temozolomide
Sensitive: C3 – Early Trials
J Clin Oncol - 1 week - (New C3)
KRAS G12C
NSCLC
selinexor + MRTX1257
Sensitive: D – Preclinical
Cancer Res Commun - 1 week - (New D)
KRAS G12C
NSCLC
sotorasib + selinexor
Sensitive: D – Preclinical
Cancer Res Commun - 1 week - (New D)
HER-2 positive
HER2 Positive Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
FDA - 2 weeks - (New A1)
No biomarker
Thyroid Gland Carcinoma
cabozantinib tablet
Sensitive: A1 - Approval
Ipsen Press Release - 2 weeks - (New A1)
PD-L1 underexpression
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
Clin Exp Immunol - 2 weeks - (New C3)
HER-2 positive
HER2 Positive Breast Cancer
nivolumab + fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
ESMO-BC 2022 - 2 weeks - (New C3)
MET mutation
NSCLC
Immunotherapy
Resistant: C3 – Early Trials
Thorac Cancer - 2 weeks - (New C3)
MYC mutation
HER2 Positive Breast Cancer
trastuzumab + atezolizumab + pertuzumab
Resistant: C3 – Early Trials
ESMO-BC 2022 - 2 weeks - (New C3)
HER-2 underexpression
Breast Cancer
eribulin mesylate
Sensitive: C3 – Early Trials
ESMO-BC 2022 - 2 weeks - (New C3)
PDSS1 overexpression
HCC
Immunotherapy
Resistant: C3 – Early Trials
Cancer Manag Res - 2 weeks - (New C3)
CD8 overexpression
Breast Cancer
paclitaxel + epirubicin
Sensitive: C3 – Early Trials
ESMO-BC 2022 - 2 weeks - (New C3)
MYC amplification + HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab + atezolizumab + pertuzumab
Resistant: C3 – Early Trials
ESMO-BC 2022 - 2 weeks - (New C3)
RAD21 amplification
HER2 Positive Breast Cancer
trastuzumab + atezolizumab + pertuzumab
Resistant: C3 – Early Trials
ESMO-BC 2022 - 2 weeks - (New C3)
MYC amplification
HER2 Positive Breast Cancer
trastuzumab + atezolizumab + pertuzumab
Resistant: C3 – Early Trials
ESMO-BC 2022 - 2 weeks - (New C3)
SMARCA4 deletion
NSCLC
PD-L1 inhibitor
Resistant: C3 – Early Trials
Lung Cancer - 2 weeks - (New C3)
EGFR expression
Nasopharyngeal Carcinoma
MRG003
Sensitive: C3 – Early Trials
JAMA Oncol - 2 weeks - (New C3)
EGFR expression
SCCHN
MRG003
Sensitive: C3 – Early Trials
JAMA Oncol - 2 weeks - (New C3)
EGFR T790M
LUAD
EGFR inhibitor
Sensitive: C3 – Early Trials
PLoS One - 2 weeks - (New C3)
RAS wild-type
CRC
anlotinib
Sensitive: C3 – Early Trials
BMC Med - 2 weeks - (New C3)
HER-2 778insGSP
Breast Cancer
trastuzumab + everolimus
Sensitive: C3 – Early Trials
Transl Oncol - 2 weeks - (New C3)
HER-2 S310F
Breast Cancer
trastuzumab + everolimus
Sensitive: C3 – Early Trials
Transl Oncol - 2 weeks - (New C3)
HRD + BRCA wild-type
Triple Negative Breast Cancer
D19466
Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 2 weeks - (New C3)
HRD + BRCA wild-type
Triple Negative Breast Cancer
carboplatin
Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 2 weeks - (New C3)
HRD
Triple Negative Breast Cancer
D19466
Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 2 weeks - (New C3)
HRD + BRCA wild-type
Triple Negative Breast Cancer
cisplatin
Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 2 weeks - (New C3)
HRD
Triple Negative Breast Cancer
carboplatin
Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 2 weeks - (New C3)
ER positive
HER2 Positive Breast Cancer
tucatinib
Sensitive: D – Preclinical
Mol Cancer Ther - 2 weeks - (New D)
TP53 mutation
Neurofibrosarcoma
AZD1775
Sensitive: D – Preclinical
Mol Cancer Ther - 2 weeks - (New D)
ADAM9 expression
Solid Tumor
IMGC936
Sensitive: D – Preclinical
Mol Cancer Ther - 2 weeks - (New D)
ERBB3 mutation
Breast Cancer
U3-1402
Sensitive: D – Preclinical
PLoS One - 2 weeks - (New D)
ALDH1A1 positive
Triple Negative Breast Cancer
EPZ-5676
Sensitive: D – Preclinical
Clin Cancer Res - 2 weeks - (New D)
MYC overexpression
NSCLC
ROS1 inhibitor
Resistant: D – Preclinical
Mol Cancer Res - 2 weeks - (New D)
HER-2 positive
Ovarian Cancer
EDIT-202
Sensitive: D – Preclinical
ASGCT 2022 - 2 weeks - (New D)
ROR1 positive
NSCLC
LYL797
Sensitive: D – Preclinical
ASGCT 2022 - 2 weeks - (New D)
ROR1 positive
Solid Tumor
LYL797
Sensitive: D – Preclinical
ASGCT 2022 - 2 weeks - (New D)
IDH1 mutation + ATRX deletion + TP53 deletion
Glioma
CAN-3110
Sensitive: D – Preclinical
ASGCT 2022 - 2 weeks - (New D)
EGFR mutation+ IDH1 R132H
NSCLC
erlotinib + AGI-5198
Sensitive: D – Preclinical
Cancer Med - 2 weeks - (New D)
MET amplification
CRC
cabozantinib tablet
Sensitive: D – Preclinical
J Pediatr Hematol Oncol - 2 weeks - (New D)
MSI-H/dMMR
Small Intestinal Carcinoma
pembrolizumab
Sensitive: A1 - Approval
Merck (MSD) Press Release - 3 weeks - (New A1)
MSI-H/dMMR
CRC
pembrolizumab
Sensitive: A1 - Approval
Merck (MSD) Press Release - 3 weeks - (New A1)
PD-L1 expression
Cervical Cancer
pembrolizumab
Sensitive: A1 - Approval
Merck (MSD) Press Release - 3 weeks - (New A1)
MSI-H/dMMR
Biliary Tract Cancer
pembrolizumab
Sensitive: A1 - Approval
Merck (MSD) Press Release - 3 weeks - (New A1)
MSI-H/dMMR
Endometrial Cancer
pembrolizumab
Sensitive: A1 - Approval
Merck (MSD) Press Release - 3 weeks - (New A1)
MSI-H/dMMR
Gastric Cancer
pembrolizumab
Sensitive: A1 - Approval
Merck (MSD) Press Release - 3 weeks - (New A1)
PD-L1 expression
Cervical Cancer
pembrolizumab + bevacizumab
Sensitive: A1 - Approval
Merck (MSD) Press Release - 3 weeks - (New A1)
HER-2 underexpression
Hormone Receptor Positive Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: B - Late Trials
Daiichi Sankyo Press Release - 3 weeks - (New B)
No biomarker
HCC
durvalumab + CP-675206
Sensitive: B - Late Trials
AstraZeneca Press Release - 3 weeks - (New B)
No biomarker
NSCLC
ONC-392
Sensitive: B - Late Trials
GlobeNewswire - 3 weeks - (New B)
No biomarker
Ovarian Cancer
VB-111
Sensitive: B - Late Trials
VBL Therapeutics Press Release - 3 weeks - (New B)
PD-L1 overexpression
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
Clin Lung Cancer - 3 weeks - (New C3)
KRAS mutation
Biliary Tract Cancer
anlotinib + APL-502
Resistant: C3 – Early Trials
Hepatology - 3 weeks - (New C3)
EGFR mutation
NSCLC
gefitinib + anlotinib
Sensitive: C3 – Early Trials
Int J Gen Med - 3 weeks - (New C3)
TMB-H
Biliary Tract Cancer
anlotinib + APL-502
Sensitive: C3 – Early Trials
Hepatology - 3 weeks - (New C3)
PD-L1 expression
Prostate Cancer
Immunotherapy
Resistant: C3 – Early Trials
Eur Urol Oncol - 3 weeks - (New C3)
KRAS mutation
NSCLC
sintilimab
Sensitive: C3 – Early Trials
J Cancer Res Clin Oncol - 3 weeks - (New C3)
SOX2 expression
Prostate Cancer
Immunotherapy
Resistant: C3 – Early Trials
Eur Urol Oncol - 3 weeks - (New C3)
PSTPIP1 overexpression
LUAD
PD-L1 inhibitor
Sensitive: C3 – Early Trials
Front Genet - 3 weeks - (New C3)
PILRA overexpression
LUAD
PD-L1 inhibitor
Sensitive: C3 – Early Trials
Front Genet - 3 weeks - (New C3)
ARID1A mutation
Cervical Cancer
bevacizumab + rucaparib
Sensitive: C3 – Early Trials
Gynecol Oncol - 3 weeks - (New C3)
ARID1A mutation
Endometrial Cancer
bevacizumab + rucaparib
Sensitive: C3 – Early Trials
Gynecol Oncol - 3 weeks - (New C3)
GSTP1 rs1138272
Breast Cancer
docetaxel + cyclophosphamide
Resistant: C3 – Early Trials
Breast Cancer Res Treat - 3 weeks - (New C3)
SLCO1B1 rs2306283
Breast Cancer
docetaxel + cyclophosphamide
Sensitive: C3 – Early Trials
Breast Cancer Res Treat - 3 weeks - (New C3)
TMEM225B rs10273424
Breast Cancer
docetaxel + epirubicin
Resistant: C3 – Early Trials
Breast Cancer Res Treat - 3 weeks - (New C3)
SLCO1B1 rs2306283
Breast Cancer
docetaxel + epirubicin
Resistant: C3 – Early Trials
Breast Cancer Res Treat - 3 weeks - (New C3)
TMEM225B rs10273424
Breast Cancer
docetaxel + cyclophosphamide
Resistant: C3 – Early Trials
Breast Cancer Res Treat - 3 weeks - (New C3)
GSTP1 rs1138272
Breast Cancer
docetaxel + epirubicin
Resistant: C3 – Early Trials
Breast Cancer Res Treat - 3 weeks - (New C3)
HR positive
HER2 Negative Breast Cancer
RP6530
Sensitive: C3 – Early Trials
Ann Oncol - 3 weeks - (New C3)
CDC25C overexpression
LUAD
nivolumab
Resistant: C3 – Early Trials
Front Oncol - 3 weeks - (New C3)
HR positive
HER2 Positive Breast Cancer
E7389-LF
Sensitive: C3 – Early Trials
Eur J Cancer - 3 weeks - (New C3)
BRAF wild-type
Melanoma
dacarbazine
Sensitive: C4 – Case Studies
J Dermatol - 3 weeks - (New C4)
BRCA1 mutation
Pancreatic Adenocarcinoma
FOLFIRI
Sensitive: C4 – Case Studies
BMJ Case Rep - 3 weeks - (New C4)
BRCA1 mutation
Pancreatic Adenocarcinoma
FOLFIRINOX
Sensitive: C4 – Case Studies
BMJ Case Rep - 3 weeks - (New C4)
KRAS mutation
CRC
MCLA-158
Sensitive: D – Preclinical
Nat Cancer - 3 weeks - (New D)
LZTS1 overexpression
Breast Cancer
paclitaxel
Sensitive: D – Preclinical
Pathol Res Pract - 3 weeks - (New D)
ER positive
Estrogen Receptor Positive Breast Cancer
MYCi975
Sensitive: D – Preclinical
Sci Adv - 3 weeks - (New D)
No biomarker
Breast Cancer
abemaciclib
Sensitive: A2 - Guideline
ASCO.org - 4 weeks - (New A2)
PD-L1 expression
Esophageal Squamous Cell Carcinoma
sintilimab
Sensitive: B - Late Trials
BMJ - 4 weeks - (New B)
No biomarker
CRC
GCC19CART
Sensitive: B - Late Trials
Innovative Cellular Therap Press Release - 4 weeks - (New B)
No biomarker
Gastroesophageal Junction Adenocarcinoma
CMG901
Sensitive: B - Late Trials
Keymed Biosci Press Release - 4 weeks - (New B)
No biomarker
Gastric Cancer
CMG901
Sensitive: B - Late Trials
Keymed Biosci Press Release - 4 weeks - (New B)
EGFR mutation + MET amplification
NSCLC
EGFR inhibitor
Resistant: C3 – Early Trials
Thorac Cancer - 4 weeks - (New C3)
MICA-L
CRC
regorafenib
Sensitive: C3 – Early Trials
BMC Cancer - 4 weeks - (New C3)
KRAS mutation + HER-2 positive
Gastric Cancer
trastuzumab
Resistant: C3 – Early Trials
J Cancer Res Clin Oncol - 4 weeks - (New C3)
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + CP-675206
Sensitive: C3 – Early Trials
NPJ Breast Cancer - 4 weeks - (New C3)
SEMA6A overexpression + BRAF mutation
Melanoma
trametinib + dabrafenib
Resistant: C3 – Early Trials
J Exp Clin Cancer Res - 4 weeks - (New C3)
KRT19 elevation
NSCLC
gimeracil / oteracil / tegafur
Sensitive: C3 – Early Trials
Respir Investig - 4 weeks - (New C3)
UGT1A1 mutation
CRC
bevacizumab
Sensitive: C3 – Early Trials
Cancer Manag Res - 4 weeks - (New C3)
HLA-E overexpression + TMB-L
NSCLC
PD1 inhibitor
Resistant: C3 – Early Trials
Front Oncol - 4 weeks - (New C3)
EGFR positive
NSCLC
gefitinib + anlotinib
Sensitive: C3 – Early Trials
Int J Gen Med - 4 weeks - (New C3)
HER-2 positive
HER2 Positive Breast Cancer
etoposide oral
Sensitive: C3 – Early Trials
Cancers (Basel) - 4 weeks - (New C3)
EGFR G719A + EGFR T790M
NSCLC
afatinib
Sensitive: C4 – Case Studies
Lung Cancer Manag - 4 weeks - (New C4)
CTNND1-ALK fusion
LUAD
alectinib
Sensitive: C4 – Case Studies
Invest New Drugs - 4 weeks - (New C4)
NUTM1-MXI1 rearrangement
Sarcoma
ICE
Sensitive: C4 – Case Studies
Diagn Cytopathol - 4 weeks - (New C4)
EGFR L858R + MET overexpression
LUAD
gefitinib
Sensitive: C4 – Case Studies
Thorac Cancer - 4 weeks - (New C4)
EGFR exon 19 deletion + MET amplification
LUAD
osimertinib + savolitinib
Sensitive: C4 – Case Studies
Thorac Cancer - 4 weeks - (New C4)
FDFT1 rearrangement + FGFR2 rearrangement
Cholangiocarcinoma
anlotinib
Sensitive: C4 – Case Studies
Cancer Treat Res Commun - 4 weeks - (New C4)
HRAS mutation
Rhabdomyosarcoma
tipifarnib
Sensitive: D – Preclinical
Oncogene - 4 weeks - (New D)
EGFR C797S + EGFR T790M + EGFR L858R
NSCLC
14aj
Sensitive: D – Preclinical
Eur J Med Chem - 4 weeks - (New D)
NRG1 overexpression
Head and Neck Cancer
cetuximab
Resistant: D – Preclinical
BMC Cancer - 4 weeks - (New D)
PD-L1 expression
NSCLC
atezolizumab
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
afatinib
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
osimertinib
Sensitive: A1 - Approval
No biomarker
NSCLC
ramucirumab
Sensitive: A1 - Approval
ALK positive
NSCLC
lorlatinib
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
gefitinib
Sensitive: A1 - Approval
PD-L1 expression
Triple Negative Breast Cancer
atezolizumab
Sensitive: A1 - Approval
EGFR L858R
NSCLC
afatinib
Sensitive: A1 - Approval
EGFR T790M
NSCLC
osimertinib
Sensitive: A1 - Approval
No biomarker
NSCLC
durvalumab
Sensitive: A1 - Approval
ALK positive
NSCLC
alectinib
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + tucatinib
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: A1 - Approval
KIT positive
GIST
imatinib
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
margetuximab
Sensitive: A1 - Approval
No biomarker
RCC
nivolumab + cabozantinib tablet
Sensitive: A1 - Approval
No biomarker
Malignant Pleural Mesothelioma
nivolumab + ipilimumab
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
pembrolizumab
Sensitive: A1 - Approval
ALK fusion
NSCLC
brigatinib
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
PDGFRA D842V
GIST
avapritinib
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
No biomarker
Esophageal Cancer
nivolumab
Sensitive: A1 - Approval
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
No biomarker
Fallopian Tube Cancer
niraparib
Sensitive: A1 - Approval
No biomarker
Ovarian Cancer
niraparib
Sensitive: A1 - Approval
No biomarker
Peritoneal Cancer
niraparib
Sensitive: A1 - Approval
KRAS G12C
NSCLC
sotorasib
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
nivolumab + ipilimumab
Sensitive: A1 - Approval
EGFR L858R
NSCLC
osimertinib
Sensitive: A1 - Approval
MSI-H/dMMR
Solid Tumor
dostarlimab
Sensitive: A1 - Approval
No biomarker
Esophageal Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
ALK positive
NSCLC
brigatinib
Sensitive: A1 - Approval
ROS1 fusion
NSCLC
entrectinib
Sensitive: A1 - Approval
No biomarker
Gastric Cancer
nivolumab
Sensitive: A1 - Approval
MET exon 14 mutation
NSCLC
tepotinib
Sensitive: A1 - Approval
No biomarker
NSCLC
bevacizumab
Sensitive: A1 - Approval
No biomarker
NSCLC
nivolumab + ipilimumab
Sensitive: A1 - Approval
EGFR L858R
NSCLC
dacomitinib
Sensitive: A1 - Approval
No biomarker
Small Cell Lung Cancer
durvalumab
Sensitive: A1 - Approval
EGFR T790M
NSCLC
lazertinib
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
dacomitinib
Sensitive: A1 - Approval
MET exon 14 mutation
NSCLC
capmatinib
Sensitive: A1 - Approval
PD-L1 overexpression
NSCLC
cemiplimab
Sensitive: A1 - Approval
RET fusion
NSCLC
pralsetinib
Sensitive: A1 - Approval
No biomarker
SCCHN
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A1 - Approval
No biomarker
Gastric Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A1 - Approval
No biomarker
NSCLC
cisplatin + pemetrexed
Sensitive: A1 - Approval
No biomarker
Breast Cancer
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive: A1 - Approval
No biomarker
BCC
fluorouracil topical
Sensitive: A1 - Approval
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
PD-L1 expression
Urothelial Cancer
atezolizumab
Sensitive: A1 - Approval
EGFR mutation
NSCLC
gefitinib
Sensitive: A1 - Approval
EGFR L858R
NSCLC
gefitinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin
Sensitive: A1 - Approval
No biomarker
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: A1 - Approval
ALK positive
NSCLC
crizotinib
Sensitive: A1 - Approval
No biomarker
NSCLC
pembrolizumab
Sensitive: A1 - Approval
ROS1 positive
NSCLC
crizotinib
Sensitive: A1 - Approval
RET fusion
NSCLC
selpercatinib
Sensitive: A1 - Approval
EGFR mutation
NSCLC
afatinib
Sensitive: A1 - Approval
EGFR exon 20 insertion
NSCLC
mobocertinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive: A1 - Approval
No biomarker
Small Cell Lung Cancer
atezolizumab
Sensitive: A1 - Approval
HER-2 positive
Gastric Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
BRCA2 mutation
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
durvalumab
Sensitive: A1 - Approval
EGFR mutation
NSCLC
erlotinib
Sensitive: A1 - Approval
PD-L1 overexpression
NSCLC
atezolizumab
Sensitive: A1 - Approval
No biomarker
HCC
pembrolizumab
Sensitive: A1 - Approval
No biomarker
HCC
bevacizumab + atezolizumab
Sensitive: A1 - Approval
BRCA1 mutation
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: A1 - Approval
RET fusion
Thyroid Gland Carcinoma
pralsetinib
Sensitive: A1 - Approval
FGFR2 rearrangement
Cholangiocarcinoma
infigratinib
Sensitive: A1 - Approval
No biomarker
NSCLC
tislelizumab
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
apalutamide
Sensitive: A1 - Approval
FGFR2 fusion
Cholangiocarcinoma
infigratinib
Sensitive: A1 - Approval
IDH1 mutation
Cholangiocarcinoma
ivosidenib
Sensitive: A1 - Approval
MSI-H/dMMR
CRC
nivolumab + ipilimumab
Sensitive: A1 - Approval
No biomarker
SCCHN
nivolumab
Sensitive: A1 - Approval
No biomarker
NSCLC
DP
Sensitive: A1 - Approval
No biomarker
Gastric Cancer
TPF
Sensitive: A1 - Approval
No biomarker
Urothelial Cancer
avelumab
Sensitive: A1 - Approval
BRCA1 mutation
Peritoneal Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
TPF
Sensitive: A1 - Approval
No biomarker
SCCHN
TPF
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive: A1 - Approval
ALK positive
NSCLC
ensartinib
Sensitive: A1 - Approval
MET exon 14 mutation
NSCLC
savolitinib
Sensitive: A1 - Approval